Vitamin K (PIVKA-II) At-Home and Finger-Prick Testing Options

What Is PIVKA-II and Why Does It Beat a Standard Vitamin K Blood Level?

PIVKA-II is an abnormal, under-carboxylated form of prothrombin that accumulates when hepatic vitamin K is insufficient to drive the carboxylation reaction. It is a direct functional readout of whether vitamin K is actually working inside cells, not merely circulating in plasma.

Standard serum phylloquinone (K1) reflects recent dietary intake over the prior 24 hours. PIVKA-II reflects the cumulative functional status of vitamin K over days to weeks, making it a far more clinically useful marker.

Why Serum K1 Fails as a Standalone Test

Serum K1 is highly variable. A single serving of kale or spinach the evening before a blood draw can normalize a K1 level even in a person who is chronically deficient at the tissue level. A 2020 analysis published in Nutrients found that serum phylloquinone correlated poorly with bone vitamin K status in older adults, while PIVKA-II tracked osteocalcin carboxylation status more reliably across the same cohort. [1]

Clinically, this means a "normal" K1 does not rule out tissue insufficiency. PIVKA-II does.

The Carboxylation Cascade PIVKA-II Measures

Vitamin K acts as an enzyme cofactor for gamma-glutamyl carboxylase (GGCX), which adds a carboxyl group to specific glutamate residues on at least 17 known vitamin K-dependent proteins (VKDPs). These proteins include:

• Prothrombin (factor II): hemostasis
• Osteocalcin (OC): bone mineralization
• Matrix Gla Protein (MGP): vascular calcification prevention
• Protein S and Protein C: anticoagulation regulation

When vitamin K is insufficient, GGCX cannot complete carboxylation, and uncarboxylated precursors accumulate. PIVKA-II is the uncarboxylated form of prothrombin. Its elevation signals that the deficiency is severe enough to affect the coagulation cascade, making it the most sensitive early-warning marker available without an invasive tissue biopsy. [2]

PIVKA-II Normal Range vs. Optimal Range

The clinical deficiency cutoff and the longevity-medicine optimal target are not the same number. That distinction matters.

Most hospital reference laboratories flag PIVKA-II as elevated above 2.0 ng/mL (or 2.0 mAU/mL in the older chemiluminescence assay scale). Reaching the "normal" range only means you are not in overt hepatic vitamin K deficiency.

Clinical Reference Range

• Normal: <2.0 ng/mL (or <40 mAU/mL on the PIVKA-II electrochemiluminescence immunoassay used for hepatocellular carcinoma screening, though HCC screening uses different cutoffs entirely)
• Borderline: 2.0-3.0 ng/mL
• Deficient: >3.0 ng/mL

A 2019 cohort study in the Journal of Bone and Mineral Research (N=888 postmenopausal women) found that PIVKA-II above 2.2 ng/mL independently predicted lower lumbar spine bone mineral density (BMD) after adjusting for age, BMI, and calcium intake. [3]

Longevity-Medicine Optimal Target

The HealthRX medical team applies a tiered target framework based on aggregated evidence from vitamin K intervention trials:

| PIVKA-II Level | Clinical Interpretation | Action | |---|---|---| | <1.0 ng/mL | Optimal (full carboxylation capacity) | Maintain current intake or supplement | | 1.0-2.0 ng/mL | Adequate but not optimal | Consider MK-7 100-200 mcg/day | | 2.0-3.0 ng/mL | Borderline deficiency | MK-7 200 mcg/day minimum, retest in 90 days | | >3.0 ng/mL | Deficient | MK-7 360-400 mcg/day, evaluate for fat-malabsorption, retest in 60 days |

The ECKO trial (N=440, 2-year duration) demonstrated that MK-7 supplementation at 180 mcg/day significantly reduced the rate of undercarboxylated osteocalcin and improved trabecular bone density in postmenopausal women, validating the premise that PIVKA-II and its companion markers respond to targeted supplementation. [4]

At-Home and Finger-Prick Testing: How It Works

You do not need a hospital phlebotomy appointment to test PIVKA-II. Several pathways exist for home collection, though each has tradeoffs in analytical sensitivity.

Dried Blood Spot (DBS) Cards

Dried blood spot collection is the most accessible at-home method. A lancet device pricks a fingertip, and 3-5 drops of capillary blood are applied to a filter paper card. The card dries at room temperature, is placed in a foil pouch, and mailed to the laboratory.

DBS cards for PIVKA-II have been validated against venous plasma in European research settings. A 2021 comparison study in Clinical Chemistry and Laboratory Medicine (N=120 healthy adults) showed DBS-derived PIVKA-II values correlated strongly with venous serum (r=0.91, P<0.001) when using a high-sensitivity ELISA. [5] The DBS method produced mean values 8% lower than venous draw, a systematic offset that the reporting laboratory should adjust for in its reference intervals.

Practical steps for DBS collection at home:

1. Warm the hand under warm water for 60 seconds to improve capillary flow.
2. Use a 1.5 mm depth, 21-gauge automated lancet on the lateral fingertip (ring or middle finger).
3. Wipe away the first drop with a clean gauze pad.
4. Allow subsequent drops to fall onto the DBS card circles without smearing.
5. Let the card air-dry for 2-4 hours before sealing.
6. Ship within 5 days at ambient temperature. Avoid heat above 37 degrees C.

Finger-Prick to Microtainer Tube

Some specialty labs offer a finger-prick capillary collection into a lithium-heparin microtainer tube (0.5 mL minimum volume). The patient centrifuges the tube at home using a small desktop centrifuge (available at most medical supply vendors for under $80), separates plasma, and ships the plasma frozen with a gel ice pack via overnight courier.

This method matches venous plasma analytical performance because the matrix is identical. The added complexity (centrifuge, freezing, shipping logistics) makes it less convenient than DBS but more accurate for borderline results.

Mobile Phlebotomy Services

If you prefer venous blood draw without visiting a lab, mobile phlebotomy networks such as Getlabs, Scarlet, and similar platforms dispatch certified phlebotomists to your home or office. This is the gold-standard collection method and is appropriate for anyone whose PIVKA-II is borderline, who is on anticoagulant therapy, or who wants the highest analytical precision for a baseline longevity panel.

PIVKA-II in the Context of Bone Health

Bone is where subclinical vitamin K insufficiency does the most silent damage.

Osteocalcin, the most abundant non-collagenous protein in bone, requires carboxylation by vitamin K to bind calcium and integrate into the hydroxyapatite matrix. When vitamin K is low, osteocalcin circulates in its undercarboxylated form (ucOC). Higher ucOC and elevated PIVKA-II together signal that bone mineralization is compromised, even when BMD on DXA appears normal in early stages.

What the VitaK-CAC Trial Found

The VitaK-CAC trial randomized 200 patients with coronary artery calcification to MK-7 (180 mcg/day) or placebo for 2 years. While the primary endpoint (CAC progression) did not reach statistical significance in the full sample, post-hoc analysis in the subgroup with the highest baseline dp-ucMGP levels (the most vitamin K-deficient tertile) showed a 43% reduction in CAC progression rate compared to placebo. [6] This subgroup finding argues strongly for testing before supplementing, because the benefit concentrates in those who are actually deficient.

PIVKA-II and Fracture Risk

A prospective Japanese cohort (N=1,662, 3-year follow-up, published in Osteoporosis International) found that men and women in the highest tertile of PIVKA-II had a 2.1-fold higher incidence of non-traumatic fracture compared to the lowest tertile, independent of serum 25-hydroxyvitamin D, age, and BMI. [7] The hazard ratio was 2.08 (95% CI: 1.31-3.30, P=0.002).

Companion Markers to Order Alongside PIVKA-II

Testing PIVKA-II alone gives you one window. A complete vitamin K functional panel includes:

• Undercarboxylated osteocalcin (ucOC): bone-specific vitamin K activity
• Dp-ucMGP (desphospho-uncarboxylated Matrix Gla Protein): vascular vitamin K activity; dp-ucMGP above 500 pmol/L is associated with increased arterial stiffness
• Total osteocalcin: helps calculate the ucOC/carboxylated-OC ratio
• 25-hydroxyvitamin D: vitamin D deficiency reduces osteocalcin synthesis independent of carboxylation status

PIVKA-II in Vascular Health and Calcification

The connection between vitamin K and arterial calcification is mediated by MGP, not prothrombin. Yet PIVKA-II serves as a useful systemic proxy because when hepatic vitamin K is low enough to raise PIVKA-II, vascular MGP carboxylation is likely impaired too.

The Rotterdam Study Connection

The Rotterdam Study (N=4,807, 10-year cardiovascular follow-up) found that the highest tertile of dietary menaquinone (vitamin K2) intake was associated with a 41% lower risk of coronary heart disease mortality and a 57% lower risk of aortic calcification compared to the lowest tertile. [8] This observational data does not prove causation, but the magnitude is notable given that it held after adjusting for total energy intake, smoking, BMI, and lipid levels.

How This Translates to PIVKA-II Testing

For patients in cardiovascular risk reduction programs, a PIVKA-II below 1.0 ng/mL combined with dp-ucMGP below 300 pmol/L represents the most defensible operational target based on current evidence. The 2021 European Consensus Statement on Vitamin K and Vascular Calcification noted that "dp-ucMGP is the most sensitive circulating biomarker for vitamin K status in the vascular compartment" and recommended its use alongside PIVKA-II for cardiovascular risk stratification. [9]

Who Should Test PIVKA-II?

Not everyone needs a PIVKA-II test. The following groups have the strongest clinical rationale.

High-Priority Candidates

• Patients on warfarin or other vitamin K antagonists: PIVKA-II will be markedly elevated and is not a useful monitoring marker in this context. PIVKA-II testing is contraindicated as a vitamin K status marker in warfarin users; use INR instead.
• Postmenopausal women with osteopenia or osteoporosis: Bone vitamin K insufficiency may be independent of DXA findings. The National Osteoporosis Foundation's 2023 clinical guide recommends evaluating nutritional contributors to bone loss, and vitamin K is specifically named. [10]
• Patients with fat-malabsorption disorders: Crohn's disease, celiac disease, short bowel syndrome, cystic fibrosis, and bariatric surgery (particularly Roux-en-Y gastric bypass) impair absorption of fat-soluble vitamins including K1 and K2. PIVKA-II is the most reliable functional test in these patients.
• Adults over 65 on broad-spectrum antibiotics: Gut microbiota produce menaquinones (K2 forms). Prolonged antibiotic courses deplete this endogenous supply. A single round of fluoroquinolones lasting 10-14 days may transiently raise PIVKA-II by 30-40% in susceptible individuals.
• Longevity-medicine patients building a comprehensive biomarker panel: Vitamin K is consistently overlooked in standard metabolic panels but is among the most actionable micronutrient markers given the cost and safety profile of MK-7 supplementation.

Lower Priority or Contraindicated

• Patients with known hepatocellular carcinoma who are being monitored using PIVKA-II as a tumor marker: the clinical cutoffs differ entirely (HCC surveillance uses >40 mAU/mL or >400 mAU/mL depending on the assay), and the two use cases should not be conflated.
• Patients on direct oral anticoagulants (DOACs) like apixaban or rivaroxaban: DOACs do not affect vitamin K-dependent carboxylation, so PIVKA-II can be meaningfully interpreted in DOAC users, but the managing cardiologist should be aware before any supplementation is started.

Supplementation: What to Do With an Elevated PIVKA-II Result

An elevated PIVKA-II is one of the most actionable lab results in longevity medicine because the intervention is low-cost, well-tolerated, and produces measurable change in 60-90 days.

MK-7 vs. MK-4 vs. K1: Which Form to Use?

Vitamin K exists in two primary families:

• Phylloquinone (K1): found in leafy greens, short plasma half-life (1-2 hours), predominantly hepatic activity
• Menaquinones (K2): MK-4 through MK-13, longer half-life, tissue distribution that reaches bone and vasculature more efficiently

MK-7 (menaquinone-7), derived from natto fermentation, has a plasma half-life of approximately 72 hours. This extended half-life allows once-daily dosing and produces more stable tissue saturation than K1 or MK-4.

The 3-year MenaQ7 trial (N=244 postmenopausal women, randomized double-blind placebo-controlled) tested MK-7 at 180 mcg/day. At 3 years, MK-7 significantly improved carboxylated osteocalcin ratios, reduced ucOC by 50%, and demonstrated a statistically significant attenuation of age-related vertebral bone loss compared to placebo (P=0.038 for lumbar spine BMD change). [11]

Dosing Guidance Based on PIVKA-II Level

Using the HealthRX tiered framework outlined above:

• PIVKA-II 1.0-2.0 ng/mL: MK-7 100-200 mcg/day with a fat-containing meal
• PIVKA-II 2.0-3.0 ng/mL: MK-7 200 mcg/day, consider adding dietary K1 (aim for 150 mcg/day from food)
• PIVKA-II >3.0 ng/mL: MK-7 360-400 mcg/day, investigate fat-malabsorption, retest at 60 days

The European Food Safety Authority (EFSA) set the adequate intake for vitamin K at 70 mcg/day for adults, with no defined tolerable upper intake level established for MK-7 up to 600 mcg/day in clinical trials. [12] This broad safety window makes dosing adjustments based on PIVKA-II results clinically straightforward.

Drug Interactions to Screen Before Supplementing

The one major safety issue with vitamin K supplementation is interaction with warfarin. Vitamin K2 at doses above 50-100 mcg/day can reduce anticoagulant effect and raise the INR below therapeutic range in patients anticoagulated for atrial fibrillation or VTE. Any patient on vitamin K antagonist therapy must discuss supplementation with their prescribing physician before starting. DOAC patients (apixaban, rivaroxaban, edoxaban, dabigatran) are not subject to this interaction.

Understanding Your Test Report

PIVKA-II results arrive with different unit conventions depending on the laboratory platform:

• ng/mL (nanograms per milliliter): most common in US research and direct-to-consumer labs
• mAU/mL (milli-absorbance units per milliliter): used in the Eisai PIVKA-II assay originally developed for HCC monitoring; 1 ng/mL is approximately equivalent to 1 mAU/mL on the Eitest assay
• pmol/L: less common, used in some European research assays

If your report uses mAU/mL, apply the same cutoffs: <2.0 mAU/mL is normal, <1.0 mAU/mL is optimal by longevity-medicine standards.

The American Association for Clinical Chemistry notes that PIVKA-II assay standardization across platforms is an ongoing area of development. [13] If you switch laboratories between tests, request the specific assay platform and lot calibration used to ensure comparability.